Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,869,939

« Back to Dashboard
Patent 6,869,939 protects NEXTERONE and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 6,869,939

Title: Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
Abstract:The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations do not require a surfactant and do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of amiodarone. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of amiodarone suitable for parenteral administration. An SAE-CD-containing formulation of amiodarone can be provided in liquid form or as a reconstitutable powder. Moreover, highly concentrated solutions exceeding 200 mg of amiodarone per mL can be prepared. Solutions can be made either dilutable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic.
Inventor(s): Mosher; Gerold L. (Kansas City, MO), Johnson; Karen T. (Lawrence, KS), Gayed; Atef A. (Overland Park, KS)
Assignee: CyDex, Inc. (Lenexa, KS)
Application Number:10/139,620
Patent Claim Types:
see list of patent claims
Formulation; Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 13th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Baxter Hlthcare
amiodarone hydrochloride
INJECTABLE;INJECTION022325-001Dec 24, 2008RXYesNo6,869,939► subscribeY
Baxter Hlthcare
amiodarone hydrochloride
INJECTABLE;INJECTION022325-002Nov 16, 2010RXYesYes6,869,939► subscribeY
Baxter Hlthcare
amiodarone hydrochloride
INJECTABLE;INJECTION022325-003Nov 16, 2010RXYesYes6,869,939► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,869,939

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2378306► subscribe
European Patent Office2402008► subscribe
European Patent Office1501496► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.